Our Pricing

Understanding Can I Get Mounjaro On NHS Costs

Published on: June 03, 2026

Understanding mounjaro nhs cost uk private options is essential for UK patients seeking this advanced weight loss treatment. While NHS availability remains limited to specific clinical trials and specialist services, private prescription routes through UK-registered pharmacies like Cured Pharmacy offer accessible alternatives with transparent pricing and rapid access to licensed tirzepatide injections.

Can I Get Mounjaro on the NHS?

Currently, Mounjaro (tirzepatide) is not routinely available through NHS prescription services for weight management in the UK. The MHRA licensed Mounjaro for weight loss in November 2023, but NICE (National Institute for Health and Care Excellence) has not yet issued guidance recommending its use within NHS weight management pathways [1].

Some NHS trusts may offer Mounjaro through specialist obesity clinics or clinical research programmes, but eligibility criteria are highly restrictive. Patients typically require a BMI above 35 with significant comorbidities, documented failed attempts with other treatments, and referral from a consultant-led service. Waiting times for specialist NHS weight management services currently exceed 12-18 months in many UK regions.

For most UK patients seeking timely access to Mounjaro, private prescription through a registered online pharmacy remains the most practical route. At Cured Pharmacy, our UK-registered prescribers assess your suitability during a free online consultation, with treatment dispatched within 24-48 hours if clinically appropriate.

Mounjaro Private Prescription Costs in the UK

Private prescription costs for Mounjaro vary significantly across UK pharmacies depending on dose strength, consultation fees, and delivery charges. At Cured Pharmacy, we guarantee the lowest prices in the UK market, with Mounjaro available from £124.99 per four-week supply.

Many patients find private prescription costs comparable to or lower than the cumulative expense of NHS prescription charges for multiple medications, particularly when factoring in the time saved avoiding lengthy specialist referral pathways. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures every prescription meets rigorous UK clinical standards while maintaining competitive pricing.

What's Included in the Price

At Cured Pharmacy, Mounjaro pricing starts from £124.99 and includes your medication, free clinical consultation with a UK prescriber, prescription processing, and discreet next-day delivery across the UK. Unlike some providers, we display transparent upfront pricing before you begin your consultation — no hidden fees or subscription traps.

Your final cost depends on the prescribed dose strength. Mounjaro is available in five dose strengths (2.5mg, 5mg, 7.5mg, 10mg, and 15mg), with treatment typically starting at the lowest dose and titrating upward over 16-20 weeks to minimise gastrointestinal side effects [2]. Our prescribers follow MHRA-approved dosing schedules to optimise both efficacy and tolerability.

How Mounjaro Works: The Science Behind Tirzepatide

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK for chronic weight management [1]. Unlike single-pathway treatments such as semaglutide (Wegovy) or liraglutide (Saxenda), tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously.

This dual mechanism produces superior metabolic effects. GLP-1 activation reduces appetite, slows gastric emptying, and improves insulin secretion, whilst GIP activation enhances these effects and may improve fat metabolism [2]. Clinical trials demonstrate this dual action translates to greater weight reduction compared to GLP-1-only treatments.

In the landmark SURMOUNT-1 trial, patients receiving the highest Mounjaro dose (15mg weekly) achieved an average 22.5% body weight reduction over 72 weeks — significantly exceeding results seen with semaglutide-based alternatives [1]. Over half of participants lost more than 20% of their starting weight, a threshold associated with substantial improvements in obesity-related comorbidities including type 2 diabetes, hypertension, and sleep apnoea.

Mounjaro Eligibility: Who Can Access Private Prescriptions

Private prescription eligibility for Mounjaro follows MHRA licensing criteria. Adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, or dyslipidaemia), may be suitable candidates subject to prescriber approval.

Unlike NHS pathways, private prescription doesn't require documented failure of multiple previous treatments or lengthy referral processes. However, responsible prescribing still necessitates clinical assessment to ensure Mounjaro is safe and appropriate for your individual circumstances. At Cured Pharmacy, our prescribers follow the same rigorous clinical standards as NHS consultants, ensuring patient safety remains paramount.

Medical Assessment Requirements

Our UK prescribers conduct a comprehensive clinical assessment covering your medical history, current medications, previous weight loss attempts, and any contraindications to GLP-1 therapy. The consultation typically takes under three minutes to complete online and is entirely free, with no obligation to proceed if Mounjaro isn't clinically suitable for you.

Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, and pregnancy or breastfeeding [2]. Your prescriber will also review potential drug interactions, particularly with insulin or sulfonylurea medications which may require dose adjustment.

Comparing Weight Loss Treatments: Finding Your Best Option

The UK weight loss medication landscape includes several evidence-based options beyond Mounjaro, each with distinct mechanisms, efficacy profiles, and cost considerations. Understanding these differences helps you make an informed choice in consultation with your prescriber.

Injectable GLP-1 receptor agonists represent the most effective pharmacological weight loss treatments currently available. Wegovy (semaglutide) and Saxenda (liraglutide) both work through single GLP-1 pathway activation, whilst Mounjaro's dual GIP/GLP-1 mechanism produces superior average weight reduction in head-to-head trials [1][3].

Oral medications like Orlistat and Xenical offer an alternative for patients preferring non-injectable treatments. These lipase inhibitors work by blocking approximately 30% of dietary fat absorption, producing modest weight loss of 5-10% when combined with calorie restriction [4]. Whilst less effective than injectable options, oral treatments suit patients with needle phobia or those seeking lower-cost entry points to medically-supervised weight management.

Your optimal treatment depends on multiple factors including your weight loss goals, medical history, budget, and personal preferences regarding injection versus oral administration. Our UK prescribers assess all these variables during your consultation to recommend the most appropriate option, whether that's Mounjaro, an alternative GLP-1 treatment, or an oral medication.

Starting Mounjaro: What to Expect from Your Treatment Journey

Mounjaro treatment begins with a 2.5mg once-weekly subcutaneous injection, administered using the pre-filled KwikPen device. The pen is designed for self-administration into the abdomen, thigh, or upper arm, with clear instructions provided with your first prescription. Most patients find the injection process straightforward after the first attempt.

Dose escalation follows a structured schedule: 2.5mg for four weeks, then 5mg for four weeks, with further increases to 7.5mg, 10mg, and potentially 15mg at four-week intervals based on your response and tolerability [2]. This gradual titration optimises both efficacy and side effect management. Your prescriber monitors your progress through follow-up consultations, adjusting the schedule if needed.

Optimal results require combining Mounjaro with sustainable lifestyle modifications. Clinical trial participants followed reduced-calorie diets (approximately 500 kcal daily deficit) and increased physical activity to at least 150 minutes of moderate exercise weekly [1]. Whilst Mounjaro significantly reduces appetite and facilitates dietary adherence, long-term weight maintenance depends on establishing healthy eating patterns and regular physical activity alongside medication.

Managing Side Effects

The most common side effects of Mounjaro are gastrointestinal, including nausea, diarrhoea, constipation, and reduced appetite [2]. These effects typically occur during dose escalation and diminish as your body adapts to treatment. Starting at the lowest dose (2.5mg) and following the gradual titration schedule significantly reduces side effect severity.

Practical strategies to minimise gastrointestinal symptoms include eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and injecting at consistent times. Most patients find symptoms resolve within 2-4 weeks of each dose increase. If side effects persist or become severe, your prescriber may slow the titration schedule or adjust your dose.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Electronic Medicines Compendium. (2024). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/14658 [accessed 13 August 2026]
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss outcomes depend on multiple factors including adherence to lifestyle modifications, baseline BMI, and individual metabolic response.